Mark Ta Donoghue

15PUBLICATIONS
298CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsNatural language processing
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Aug 14, 2026
The pan-tumor landscape, allelic status, and genomic complexity of SMARCA4 alterations.

|Jun 24, 2026
The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid Tumors.

|Mar 26, 2026
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.

Wungki Park, Catherine A O'Connor, Joanne F Chou

|Mar 04, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.

Anton Safonov, Minna Lee, David N Brown

|Feb 02, 2026
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.

Brendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran

|Sep 15, 2025
Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial.

Wungki Park, Catherine O'Connor, Joanne Chou

Pageof 3

Frequent Collaborators

9 joint publications

Michael F Berger

6 joint publications

Marc Ladanyi

5 joint publications

David B Solit

5 joint publications

Chaitanya Bandlamudi